Ocera Therapeutics

Ocera’s lead drug candidate OCR-002 is a novel ammonia scavenger which rapidly removes ammonia from the blood. Elevated ammonia is believed to be one of the primary causes of hepatic encephalopathy (HE). OCR-002 is the subject of STOP-HE, a Company-sponsored Phase 2b trial, and two investigator-sponsored Phase 2a trials. OCR-002 has received Orphan Drug designation in both the U.S. and Europe and has been granted Fast Track status by the U.S. Food and Drug Administration.

Company Growth (employees)
Palo Alto, US
Size (employees)
20 (est)
Ocera Therapeutics was founded in 2005 and is headquartered in Palo Alto, US

Ocera Therapeutics Office Locations

Ocera Therapeutics has offices in Palo Alto, Durham
Palo Alto, US
Durham, US

Ocera Therapeutics Metrics

Ocera Therapeutics Summary

Market capitalization

$30.2 m

Closing share price

Ocera Therapeutics's current market capitalization is $30.2 m.

Ocera Therapeutics Market Value History

Ocera Therapeutics Online Presence

Ocera Therapeutics Company Life

You may also be interested in